THE SAFETY AND EFFICACY OF Cymbopogon citratus Stapf. EXTRACT IN CHRONIC KIDNEY DISEASE PATIENTS STAGE 3B; A DOUBLE BLIND RANDOMIZE CONTROL TRIA
- Registration Number
- TCTR20230720001
- Lead Sponsor
- THAI TRADITIONALMEDICALKNOWLEDGE FUND, Thailand
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 64
1.Male or female participants aged between 35- 85 years
2.Participants with stage 3B chronic kidney disease and had an eGFR between 30-44 ml / min / 173m2.
1.Participants with cancer of all types from the first stage onwards
2.Participants with heart disease or heart abnormality in all cases
3.Participants with liver disease, hepatitis, cirrhosis, fatty liver
4.Participants with diabetic nephropathy
5.Participants with chronic infection and are undergoing treatment for an infection
6.Participants with alcoholism
7.Participants with autoimmune disease, SLE, rheumatoid arthritis and are taking corticosteroids, immunosuppressants or immunosuppressive agents
8.Participants with during of pregnant or breastfeeding
9.Participants with history of lemongrass allergy
10.Participants with prolonged obstruction of the urinary tract, such as enlarged prostate and kidney stones
11.Participants with overactive bladder (OAB)
12.Participants currently participating in another study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method urinary angiotensinogen pre-post treatment 90 day Urine ,TGF-beta pre-post treatment (90 day) Urine,Nitric oxide (NO) pre post treatment (90 day) Urine,interleukin 6 (IL-6) pre-post treatment (90 day) Blood,Ultrasound Doppler for Resistive index (RRI) pre-post treatment (90 day) Ultrasonography, BUN, Creatinine, Electrolyte, eGFR, CBC, LFT Baseline, monthly for 3 time Blood,FBS, Cystatin C, hs-CRP, Phosphorus, Calcium, Magnesium, uric acid pre-post treatment (90 day) Blood,Urine examination (UA) Baseline, monthly for 3 time Urine,urine 24 hr. pre-post treatment and day 10 in periods study Urine
- Secondary Outcome Measures
Name Time Method Quality of life pre-post treatment (90 day) Kidney Disease Quality of Life Short Form - KDQOL SFTM version 1.3